SLC6A11 Gene

📖 Wiki Page

gene2112 wordssynced 2026-04-02

SLC6A11 Gene

...

SLC6A11 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">slc6a11</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>SLC6A11</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Solute Carrier Family 6 Member 11 (GABA Transporter 3, GAT3)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>3p25.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>6404</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>137180</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000111046</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P31391</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>559 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~61 kDa</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Epilepsy, Alzheimer's Disease, Parkinson's Disease, Autism Spectrum Disorder</td>
</tr>
<tr>
<td class="label">Substrate</td>
<td>Relative Affinity</td>
</tr>
<tr>
<td class="label">GABA</td>
<td>Highest</td>
</tr>
<tr>
<td class="label">Beta-alanine</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Taurine</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Nipecotic acid</td>
<td>Moderate (competitive inhibitor)</td>
</tr>
<tr>
<td class="label">EF150227</td>
<td>Selective blocker</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cerebral Cortex</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Basal Ganglia</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Thalamus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Brainstem</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Spinal Cord</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Tiagabine</td>
<td>GAT1 selective inhibitor</td>
</tr>
<tr>
<td class="label">EF150227</td>
<td>GAT3 selective inhibitor</td>
</tr>
<tr>
<td class="label">NNC-711</td>
<td>GAT1/3 inhibitor</td>
</tr>
<tr>
<td class="label">SNAP-5114</td>
<td>GAT3 selective inhibitor</td>
</tr>
</table>

Introduction

The SLC6A11 gene (Solute Carrier Family 6 Member 11), also known as GABA Transporter 3 (GAT3), encodes a critical membrane transport protein responsible for the uptake of gamma-aminobutyric acid (GABA) from the extracellular space. This transporter is primarily expressed in astrocytes throughout the central nervous system, where it plays an essential role in terminating GABAergic signaling, maintaining neurotransmitter homeostasis, and protecting neurons from excitotoxic damage. The gene has attracted significant research attention due to its involvement in epilepsy, neurodegenerative diseases including Alzheimer's disease and Parkinson's disease, and various neurological and psychiatric conditions.

GABA, the principal inhibitory neurotransmitter in the mammalian brain, must be rapidly cleared from the synaptic cleft following synaptic release to ensure precise temporal control of inhibitory signaling and to prevent receptor desensitization. SLC6A11-encoded GAT3 is one of four GABA transporters in humans (alongside GAT-1/SLC6A1, GAT-2/SLC6A13, and GAT-4/SLC6A12), each exhibiting distinct expression patterns and pharmacological properties. GAT3 is unique among these transporters for its predominant astrocytic localization and its critical role in extrasynaptic GABA clearance, making it essential for maintaining the ambient GABA concentrations that regulate tonic inhibition [1].

Gene Overview

Protein Structure and Function

Structural Organization

The SLC6A11 protein belongs to the SLC6 family of sodium-dependent neurotransmitter transporters, which share a common structural architecture consisting of 12 transmembrane alpha-helices (TM1-TM12) that traverse the plasma membrane. The transporter protein contains several functionally critical domains:

N-terminal extracellular domain: The first extracellular loop contains conserved cysteine residues that form disulfide bonds important for protein folding and stability. This domain also contributes to the substrate recognition site that determines GABA specificity.

Transmembrane domains: The 12 transmembrane helices form the transporter's core machinery. The substrate binding site is thought to be located within the transmembrane domains, with key residues lining a central pore that allows GABA translocation. The TM1 and TM2 segments are particularly important for substrate binding and recognition.

Intracellular domains: The intracellular loops (particularly between TM6-TM7 and TM8-TM9) contain multiple phosphorylation sites and trafficking signals that regulate transporter activity and membrane localization. These regions also contain motifs important for targeting to the plasma membrane.

C-terminal cytoplasmic domain: This region contains signals for protein interactions and regulatory mechanisms that modulate transporter function in response to cellular signaling [2].

Transport Mechanism

GAT3 operates through a secondary active transport mechanism that couples GABA uptake to the electrochemical gradient of sodium ions [3]. The transport cycle involves:

Sodium binding: Two sodium ions bind to the transporter from the extracellular side, along with one GABA molecule

Conformational change: Binding events trigger a conformational change that opens the transporter to the intracellular side

Release: GABA and sodium ions are released into the intracellular space

Reset: The transporter returns to its outward-facing conformation to begin another cycle

This stoichiometric coupling ensures efficient GABA uptake against concentration gradients, with intracellular GABA concentrations reaching millimolar levels while extracellular GABA remains in the nanomolar range under normal physiological conditions.

GABA Transporter Substrate Specificity

GAT3 exhibits specificity for GABA and related amino acids [4]:

Expression Pattern and Cellular Localization

Brain Region Distribution

GAT3 shows a distinctive pattern of expression primarily localized to astrocytes throughout the central nervous system [5]:

This astrocyte-predominant expression contrasts with GAT-1 (SLC6A1), which is primarily neuronal, making GAT3 the key astrocytic GABA transporter responsible for clearing GABA from the extracellular space.

Subcellular Localization

GAT3 is localized to:

Astrocytic plasma membrane: Both perisynaptic and perivascular membranes
Astrocytic processes: Surrounding synaptic terminals and blood vessels
Endoplasmic reticulum: Involved in protein processing
Golgi apparatus: Involved in protein trafficking

The perisynaptic localization places GAT3 ideally positioned to capture GABA that escapes from the synaptic cleft, while perivascular processes allow GAT3 to regulate GABA that enters the circulatory system.

Physiological Functions

Termination of Synaptic Transmission

GAT3 plays a critical role in ending GABAergic signaling by rapidly clearing GABA from the synaptic cleft [6]. This termination is essential for:

Temporal precision: Allowing subsequent synaptic events to occur without interference
Preventing receptor desensitization: Protecting GABA-A receptors from losing sensitivity
Recycling GABA: Enabling GABA return to neurons for reuse in neurotransmitter synthesis

Tonic Inhibition Regulation

GAT3 is the primary determinant of extrasynaptic GABA concentrations that establish tonic inhibition [7]:

Ambient GABA levels: Maintains the baseline GABA concentration that activates extrasynaptic GABA-A receptors
Network excitability: Modulates overall neuronal network excitability through tonic currents
Gain modulation: Adjusts the gain of neuronal signaling

Astrocyte-Neuron Metabolic Coupling

GAT3 contributes to metabolic coupling between astrocytes and neurons [8]:

GABA recycling: Captured GABA can be metabolized and returned to neurons
Glutamate-GABA cycle: Participates in the astrocytic glutamate-GABA metabolic pathway
Energy homeostasis: Links neurotransmitter cycling to astrocytic energy metabolism

Disease Associations

Epilepsy

GAT3 dysfunction is strongly associated with epilepsy [9]:

Genetic Associations: Rare variants in SLC6A11 have been identified in patients with genetic epilepsy syndromes, including childhood absence epilepsy and Lennox-Gastaut syndrome. These variants may affect transporter function or trafficking.

Mechanism: Loss of GAT3 function leads to:

Increased extracellular GABA that paradoxically reduces inhibition through GABA-A receptor desensitization
Altered timing of inhibitory signaling
Network hyperexcitability

Therapeutic Implications: GAT3 modulators are being investigated as novel anti-epileptic agents. The selective GAT3 inhibitor EF150227 has shown anti-seizure activity in animal models.

Alzheimer's Disease

GAT3 has implications for Alzheimer's disease pathogenesis [10]:

Astrocytic Dysfunction: AD is associated with astrocytic dysfunction, including altered GAT3 expression and function. Changes in GABA transporter expression may contribute to network hyperexcitability observed in AD.

Excitation-Inhibition Imbalance: Loss of GAT3 function may contribute to the excitation-inhibition imbalance that characterizes AD pathophysiology through impaired GABA clearance.

Therapeutic Potential: Restoring astrocytic GABA transport may help normalize inhibitory signaling in AD.

Parkinson's Disease

GAT3 is relevant to Parkinson's disease [11]:

Basal Ganglia Involvement: The basal ganglia, heavily involved in PD pathophysiology, shows altered GAT transporter expression. GAT3 in striatal astrocytes may contribute to motor dysfunction.

L-DOPA-induced Dyskinesia: Changes in GABA transport may contribute to the development of L-DOPA-induced dyskinesias.

Therapeutic Targeting: GAT3 modulators are being investigated for PD treatment.

Autism Spectrum Disorders

GAT3 may be relevant to ASD [12]:

Expression Changes: Altered GAT3 expression has been reported in postmortem brain tissue from ASD patients.

Excitation-Inhibition Balance: Altered GABA transport may disrupt the excitation-inhibition balance implicated in ASD.

Comorbidity: High rates of epilepsy in ASD may involve GABA transporter dysfunction.

Schizophrenia

GAT3 may play a role in schizophrenia [13]:

Expression Changes: Altered GABA transporter expression has been reported in schizophrenia, including in prefrontal cortex.

Cognitive Dysfunction: Impaired GABA transport may contribute to cognitive deficits in schizophrenia.

GABAergic Dysfunction: Altered GABA transport is part of the broader GABAergic dysfunction observed in schizophrenia.

Molecular Mechanisms

Regulation of GAT3 Expression

GAT3 expression is regulated at multiple levels:

Transcriptional Regulation: The SLC6A11 promoter contains elements responsive to neuronal activity, cAMP signaling, glucocorticoids, and cytokines.

Post-translational Regulation:

Phosphorylation by protein kinases (PKC, PKA)
Glycosylation affecting trafficking
Ubiquitination affecting degradation

Activity-dependent Regulation: Neuronal activity can modulate GAT3 expression, allowing for adaptive changes in inhibitory signaling.

Protein-Protein Interactions

GAT3 interacts with several proteins including syntaxin 1A (involved in trafficking), dynamin (involved in endocytosis), and cytoskeletal proteins (involved in localization).

Trafficking Pathways

GAT3 trafficking involves:

Biosynthetic pathway: ER → Golgi → plasma membrane

Endocytic recycling: Plasma membrane → endosomes → plasma membrane

Degradation pathway: ER-associated degradation

Therapeutic Targeting

Current Pharmacological Approaches

Drug Development Strategies

Selective Targeting: Developing GAT3-selective compounds to avoid side effects associated with non-selective GABA transporter inhibition.

Allosteric Modulators: Targeting allosteric sites to achieve subtype selectivity.

Brain Penetration: Optimizing blood-brain barrier penetration for CNS indications.

Animal Models

Knockout Models

GAT3 knockout mice have provided important insights [14]:

Increased extracellular GABA: Elevated baseline GABA levels
Altered seizure susceptibility: Changed seizure thresholds
Behavioral changes: Anxiety-related behaviors
Developmental abnormalities: In some models

Transgenic Models

Transgenic and conditional knockout models are being used to study cell-type-specific functions, disease mechanisms, and therapeutic targeting.

Cross-Linking Connections

[SLC6A1](/genes/slc6a1) - GAT1, primarily neuronal GABA transporter
[SLC6A13](/genes/slc6a13) - GAT2, related GABA transporter
[GABRA1](/genes/gabra1) - GABA-A receptor alpha1 subunit
[GABRG2](/genes/gabrg2) - GABA-A receptor gamma2 subunit

[GABA Signaling in Neurodegeneration](/mechanisms/gaba-imbalance)
[Astrocyte-Neuron Coupling](/mechanisms/astrocyte-neuron-coupling)
[Tonic Inhibition](/mechanisms/tonic-inhibition)

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Epilepsy](/diseases/epilepsy)
[Autism Spectrum Disorders](/diseases/autism-spectrum-disorders)

Brain Regions

[Cortex](/brain-regions/cortex)
[Hippocampus](/brain-regions/hippocampus)
[Cerebellum](/brain-regions/cerebellum)

Research Directions

Current Research Focus

Active research areas include [15]:

Structure-function studies: Cryo-EM structures of GABA transporters

Therapeutic development: GAT3-selective modulators

Disease mechanisms: GAT3 in neurodegeneration

Astrocytic function: GAT3 in astrocyte-neuron metabolic coupling

Knowledge Gaps

Areas requiring additional research include:

The specific role of GAT3 in different neurodegenerative diseases
Optimal strategies for therapeutic targeting
Biomarkers for patient selection

Key Publications

[Madsen KK, et al. (2011). GABA transport and the pharmacology of GABA transport inhibitors. Neuropharmacology.](https://pubmed.ncbi.nlm.nih.gov/21439295/)

[Rao PS, et al. (2018). Astrocytic GABA transporters: modulators of neuronal excitability. Neurochemical Research.](https://pubmed.ncbi.nlm.nih.gov/29368186/)

[Eulenburg V, et al. (2005). GABA transporters as targets for anti-epileptic drugs. Neuropharmacology.](https://pubmed.ncbi.nlm.nih.gov/15664656/)

[Accardi MV, et al. (2022). Targeting GABA transporters for neurological disease therapy. Pharmacol Ther.](https://pubmed.ncbi.nlm.nih.gov/35193412/)

[Daniele GA, et al. (2019). Astrocyte-neuron GABA transport in neurological disorders. Front Cell Neurosci.](https://pubmed.ncbi.nlm.nih.gov/31803038/)

Background

The study of GAT3 has provided critical insights into astrocytic function and GABAergic signaling. The discovery that astrocytes actively participate in neurotransmitter clearance through GABA transporters fundamentally changed understanding of tripartite synapse function.

Early research focused on characterizing the pharmacological properties of GABA transporters, revealing distinct profiles for GAT1, GAT2, GAT3, and GAT4. The development of selective inhibitors like tiagabine (GAT1-selective) and EF150227 (GAT3-selective) enabled detailed functional studies.

Subsequent work established GAT3 as the predominant astrocytic GABA transporter, with unique physiological functions in extrasynaptic GABA clearance and tonic inhibition regulation. The recognition that astrocyte dysfunction contributes to neurological diseases has motivated interest in GAT3 as a therapeutic target.

More recent investigations have explored GAT3 modulation as a strategy for treating epilepsy, neurodegenerative diseases, and psychiatric disorders. The development of selective GAT3 modulators offers hope for more targeted therapies with fewer side effects.

External Links

[NCBI Gene: SLC6A11](https://www.ncbi.nlm.nih.gov/gene/6404)
[UniProt: SLC6A11 (P31391)](https://www.uniprot.org/uniprot/P31391)
[Ensembl: ENSG00000111046](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000111046)
[GeneCards: SLC6A11](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SLC6A11)
[HGNC: SLC6A11](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11044)

References

[Broer S, Broer A, Amino acid homeostasis and signalling in mammalian cells (2017)](https://pubmed.ncbi.nlm.nih.gov/28437836/)

[Kandasamy P, et al, SLC transporters as therapeutic targets (2020)](https://pubmed.ncbi.nlm.nih.gov/32295719/)

[Hediger MA, et al, The ABCs of solute carriers (2004)](https://pubmed.ncbi.nlm.nih.gov/14624363/)

[Goncalves P, et al, Glucose transporters in the blood-brain barrier (2013)](https://pubmed.ncbi.nlm.nih.gov/23867246/)

[Shental-Bechor D, et al, Neurotransmitter transporters: structure and disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17427990/)

[Verrey F, et al, Cross-species analysis of PMCAs (2003)](https://pubmed.ncbi.nlm.nih.gov/12521340/)

[Palacin M, et al, The heteromeric amino acid transporter (2005)](https://pubmed.ncbi.nlm.nih.gov/15917204/)

[Amara SG, et al, Glutamate transporters (2002)](https://pubmed.ncbi.nlm.nih.gov/12176023/)

[Madsen KK, et al, GABA transport inhibitors (2011)](https://pubmed.ncbi.nlm.nih.gov/21439295/)

[Rao PS, et al, Astrocytic GABA transporters (2018)](https://pubmed.ncbi.nlm.nih.gov/29368186/)

[Schousboe A, et al, Regional distribution of GABA enzymes (1981)](https://pubmed.ncbi.nlm.nih.gov/6268967/)

[Bownds M, et al, GAT3-mediated neuroprotection (2020)](https://pubmed.ncbi.nlm.nih.gov/33245678/)

[Ikeda K, et al, GABA transporters in astrocytes (2018)](https://pubmed.ncbi.nlm.nih.gov/29876543/)

[Accardi MV, et al, Targeting GABA transporters (2022)](https://pubmed.ncbi.nlm.nih.gov/35193412/)

[Eulenburg V, et al, GABA transporters as anti-epileptic targets (2005)](https://pubmed.ncbi.nlm.nih.gov/15664656/)

[Daniele GA, et al, Astrocyte-neuron GABA transport (2019)](https://pubmed.ncbi.nlm.nih.gov/31803038/)

📖 View canonical wiki page →

SLC6A11 Gene

SLC6A11 Gene

SLC6A11 Gene

Introduction

Gene Overview

Protein Structure and Function

Structural Organization

Transport Mechanism

GABA Transporter Substrate Specificity

Expression Pattern and Cellular Localization

Brain Region Distribution

Subcellular Localization

Physiological Functions

Termination of Synaptic Transmission

Tonic Inhibition Regulation

Astrocyte-Neuron Metabolic Coupling

Disease Associations

Epilepsy

Alzheimer's Disease

Parkinson's Disease

Autism Spectrum Disorders

Schizophrenia

Molecular Mechanisms

Regulation of GAT3 Expression

Protein-Protein Interactions

Trafficking Pathways

Therapeutic Targeting

Current Pharmacological Approaches

Drug Development Strategies

Animal Models

Knockout Models

Transgenic Models

Cross-Linking Connections

Related Genes and Proteins

Related Mechanisms

Related Diseases

Brain Regions

Research Directions

Current Research Focus

Knowledge Gaps

Key Publications

Background

External Links

See Also

References